BIOMAT Database Logo BIOMAT Database Logo

The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors. 1990

G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Division of Endocrine Oncology (Biochemistry and Endocrinology), Dr. Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands.

The effects of treatment with a somatostatin analog (Sandostatin, SMS201-995) were investigated in female rats with dimethylbenzanthracene (DMBA)-induced rat mammary tumors. A 3-week treatment was performed using sandostatin, the LHRH-agonist buserelin alone, or buserelin in combination with sandostatin. Twice daily sandostatin treatment was performed with dosages of 0.05 microgram, 0.2 microgram, 1 microgram, 5 micrograms, and 20 micrograms. Buserelin was used in a 2 x 5 micrograms/day dosage. The combined results from six different experiments show that the various dosages of sandostatin caused no tumor growth inhibition. Somatostatin receptors could not be demonstrated in these mammary tumors. Sandostatin treatment by daily injections did not suppress levels of growth hormone, prolactin, or epidermal growth factor-like activities. Estrogen (ER) and progesterone (PgR) receptor contents of the mammary tumors were not changed. In contrast, buserelin treatment caused highly significant tumor remission. The combined treatment with sandostatin and buserelin did not alter the treatment results obtained after treatment with buserelin alone. In conclusion, sandostatin treatment in this tumor model had no direct growth inhibitory effect and did not cause an endocrine inhibition of mammary tumor growth. However, these results do not exclude antitumor effects in human breast cancer in view of the presence of somatostatin receptors in approximately 20-45% of human tumors, besides possible different endocrine effects.

UI MeSH Term Description Entries
D008325 Mammary Neoplasms, Experimental Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS. Experimental Mammary Neoplasms,Neoplasms, Experimental Mammary,Experimental Mammary Neoplasm,Mammary Neoplasm, Experimental,Neoplasm, Experimental Mammary
D010908 Pituitary Hormones, Anterior Hormones secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Structurally, they include polypeptide, protein, and glycoprotein molecules. Adenohypophyseal Hormones,Anterior Pituitary Hormones,Hormones, Adenohypophyseal,Hormones, Anterior Pituitary
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011987 Receptors, Steroid Proteins found usually in the cytoplasm or nucleus that specifically bind steroid hormones and trigger changes influencing the behavior of cells. The steroid receptor-steroid hormone complex regulates the transcription of specific genes. Corticosteroid Receptors,Receptors, Corticosteroid,Steroid Receptors,Corticosteroid Receptor,Receptors, Steroids,Steroid Receptor,Receptor, Corticosteroid,Receptor, Steroid,Steroids Receptors
D002064 Buserelin A potent synthetic analog of GONADOTROPIN-RELEASING HORMONE with D-serine substitution at residue 6, glycine10 deletion, and other modifications. Bigonist,Buserelin Acetate,HOE-766,Profact,Receptal,Suprecur,Suprefact,Tiloryth,Acetate, Buserelin,HOE 766,HOE766
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015127 9,10-Dimethyl-1,2-benzanthracene Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen. 7,12-Dimethylbenzanthracene,7,12-Dimethylbenz(a)anthracene,7,12 Dimethylbenzanthracene
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995

Related Publications

G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Actions of a long-acting somatostatin analog SMS201-995 (sandostatin) on rat locus coeruleus neurons.
January 1994, Life sciences,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Effect of SMS201-995 (a long-acting somatostatin analog) on bile-induced acute hemorrhagic pancreatitis in the dog.
June 1989, The American surgeon,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
[Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
October 1988, Zeitschrift fur Gastroenterologie,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Effect of somatostatin analogue (SMS201-995) on cyclosporine levels.
November 1987, Transplantation,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Immunohistochemical studies of DMBA-induced rat mammary tumors.
February 1988, Acta pathologica japonica,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
[The pharmacological treatment of digestive endocrine tumors with the somatostatin analog SMS 201-995].
January 1991, Revista clinica espanola,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). I. An open-label pilot study.
January 1990, Cleveland Clinic journal of medicine,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Absence of Ras mutations in rat DMBA-induced mammary tumors.
February 2009, Molecular carcinogenesis,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Treatment of psoriasis with chronic subcutaneous administration of somatostatin analog 201-995 (sandostatin). II. Effect on pancreatic and thyroid hormone.
January 1990, Cleveland Clinic journal of medicine,
G H Bakker, and B Setyono-Han, and J A Foekens, and H Portengen, and W L van Putten, and F H de Jong, and S W Lamberts, and J C Reubi, and J G Klijn
Treatment of Cushing's syndrome with the long-acting somatostatin analogue SMS 201-995 (sandostatin).
March 1990, Clinical endocrinology,
Copied contents to your clipboard!